Colossal Biosciences

Who are Colossal Biosciences's decision-makers?

Colossal Biosciences is led by Ben Lamm, Co-founder and CEO, with a leadership bench spanning product, science, operations, and commercialization.

CEO
Ben Lamm
Key exec
George Church
Founded
2021
Employees
Private; reported 170+ employees in 2025 coverage
HQ
Dallas, Texas
Notable
Serial entrepreneur leading commercialization and partnerships.
  • Ben LammCo-founder and CEOCo-founder · since 2021Serial entrepreneur leading commercialization and partnerships.
  • George ChurchCo-founderCo-founderHarvard geneticist and synthetic-biology pioneer.
  • Andrew PaskChief Biology Officer / Thylacine leadExecutiveLeads thylacine restoration work and Australian expansion.

Who leads Colossal Biosciences?

Ben Lamm serves as Co-founder and CEO; George Church serves as Co-founder; Andrew Pask serves as Chief Biology Officer / Thylacine lead. The leadership pattern reflects the company's focus on de-extinction biotechnology.

For outreach, leadership background matters because it shows whether decisions are likely to be product-led, science-led, clinical, industrial, or government-procurement heavy.

Who actually makes buying decisions at Colossal Biosciences?

Likely buying committees include the executive owner of Mammoth program, security and compliance leaders, finance/procurement, and the technical leaders responsible for integration.

A seller should avoid starting with a generic CEO pitch unless the offer is strategic. Most practical deals will need a functional champion who owns deployment pain and a finance or operations approver.

How is Colossal Biosciences organized as it scales?

Colossal Biosciences's public footprint suggests a scaling private company with cross-functional teams around product, engineering, customer deployment, and go-to-market or R&D. Exact reporting lines are not public.

The safest assumption is a matrixed buying process: technical validation first, operational proof second, and executive approval for larger commitments.

As of June 2026.Sources:Colossal websiteColossal news

Colossal Biosciences — frequently asked questions

Agent CTA Background

Revenue work. On autopilot.

Start Free TrialBuilt for revenue teams who care about quality.